F S&P 500
5,092.00 -12.00 (-0.24%) F Dow Jones
37,901.00 -92.00 (-0.24%) F Nasdaq
17,838.50 -37.75 (-0.21%) E-mini Russell 2000 Index Futur
1,984.40 -6.60 (-0.33%) Petróleo
85.87 +0.46 (+0.54%) Oro
2,400.50 +17.50 (+0.73%)
Cidara Therapeutics, Inc. (CDTX)
Fuera de horario:
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive
Suite 101
San Diego, CA 92121
United States
858 752 6170
https://www.cidara.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 73
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jeffrey L. Stein Ph.D. | President, CEO & Executive Director | 873.25k | N/D | 1955 |
| Dr. Preetam Shah M.B.A., Ph.D. | CFO, Chief Business Officer & Principal Accounting Officer | 577.85k | N/D | 1973 |
| Dr. Taylor Sandison | Chief Medical Officer | 632.05k | N/D | 1972 |
| Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer | 333.31k | N/D | 1977 |
| Mr. Shane M. Ward | COO & Chief Legal Officer | N/D | N/D | 1975 |
| Ms. Allison Lewis CCP, SPHR | Senior Vice President of People & Culture | N/D | N/D | N/D |
| Dr. Leslie Tari Ph.D. | Chief Scientific Officer | 845.1k | N/D | 1967 |
| Ms. Laura A. Navalta | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
| Dr. Nicole Davarpanah J.D., M.D. | Senior VP of Translational Research & Development | N/D | N/D | N/D |
Descripción
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Cidara Therapeutics, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 6; Derechos del accionista: 8; Compensación: 9.
